公开(公告)号：US20170172991A1

公开(公告)日：2017-06-22

申请号：US15383983

申请日：2016-12-19

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Jessica Reedy ,  Christopher Pigge ,  Moustafa Tarek Ahmed Ibrahim Gabr

IPC: A61K31/444 ,  A61K31/4409 ,  A61K49/00

CPC classification number: A61K31/444 ,  A61K31/4409 ,  A61K49/0021

Abstract: The invention provides a method to treat cancer in an animal comprising administering a tetra-arylethylene cation to the animal.

公开(公告)号：US12128115B2

公开(公告)日：2024-10-29

申请号：US17051037

申请日：2019-04-25

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Christopher Pigge ,  Mengshi Li ,  Moustafa Gabr ,  Edwin Sagastume

IPC: A61K51/04 ,  A61K45/06 ,  A61K51/08

CPC classification number: A61K51/0482 ,  A61K45/06 ,  A61K51/0497 ,  A61K51/083

Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(═O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

公开(公告)号：US11529335B2

公开(公告)日：2022-12-20

申请号：US16945323

申请日：2020-07-31

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Somya Kapoor ,  Douglas R. Spitz

IPC: A61K31/437 ,  A61P35/04 ,  A61K31/198 ,  A61K31/4706 ,  A61K31/66 ,  C07K16/28

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

公开(公告)号：US20210228749A1

公开(公告)日：2021-07-29

申请号：US17051037

申请日：2019-04-25

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Christopher Pigge ,  Mengshi Li ,  Moustafa Gabr ,  Edwin Sagastume

IPC: A61K51/04 ,  A61K51/08 ,  A61K45/06

Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(═O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

公开(公告)号：US10729669B2

公开(公告)日：2020-08-04

申请号：US15748506

申请日：2016-07-26

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Somya Kapoor ,  Andrean L. Simons-Burnett

IPC: A61K31/192 ,  A61K31/437 ,  A61K31/4706 ,  A61K31/662 ,  A61P35/00 ,  A61K31/66 ,  A61K39/395 ,  C07K16/28

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.

公开(公告)号：US20240366816A1

公开(公告)日：2024-11-07

申请号：US18771562

申请日：2024-07-12

Applicant: University of Iowa Research Foundation

Inventor： Dongyoul Lee ,  Michael K. Schultz ,  Mengshi Li ,  Nicholas Baumhover ,  F. Christopher Pigge

IPC: A61K51/10 ,  A61K51/08 ,  A61P35/00

Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

公开(公告)号：US11596613B2

公开(公告)日：2023-03-07

申请号：US16945327

申请日：2020-07-31

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Somya Kapoor ,  Douglas R. Spitz

IPC: A61K31/192 ,  A61K31/437 ,  A61K31/4706 ,  A61K31/662 ,  A61P35/00 ,  A61K31/66 ,  A61K39/395 ,  C07K16/28

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

公开(公告)号：US11179484B2

公开(公告)日：2021-11-23

申请号：US16312846

申请日：2017-06-26

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Frances L. Johnson ,  Somya Kapoor ,  Dongyoul Lee ,  Mengshi Li ,  Molly Martin

IPC: A61K51/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/08 ,  A61K47/54 ,  A61K47/60 ,  A61K31/167 ,  A61K31/192 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/519

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

公开(公告)号：US20210113503A1

公开(公告)日：2021-04-22

申请号：US16945327

申请日：2020-07-31

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Somya Kapoor ,  Douglas R. Spitz

IPC: A61K31/192 ,  A61K31/437 ,  A61K31/4706 ,  A61K31/662 ,  A61P35/00 ,  A61K31/66 ,  A61K39/395 ,  C07K16/28

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

公开(公告)号：US20200147060A1

公开(公告)日：2020-05-14

申请号：US16668736

申请日：2019-10-30

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Somya Kapoor ,  Douglas R. Spitz ,  Andrean Burnett ,  Ling Yang

IPC: A61K31/437 ,  A61K31/197 ,  A61K31/192 ,  A61K31/472 ,  A61P35/00

Abstract: The invention provides in certain embodiments a therapeutic regimen comprising (a) an anti-cancer combination of vemurafenib and cobimetinib, or a combination of trametinib and dabrafenib, and (b) a secondary agent comprising L-buthionine-[S,R]-sulfoximine (BSO), or phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof, and chloroquine or hydrochloroquine (HCQ) for the therapeutic treatment of a hyperproliferative disorder.